Global Amifampridine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amifampridine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Amifampridine (pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form
Amifampridine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amifampridine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Myasthenia Gravis and Potassium Channel Blocker are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Amifampridine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Amifampridine key manufacturers include Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG and Innovapharm, etc. Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical are top 3 players and held % sales share in total in 2022.
Amifampridine can be divided into Generic and Patent, etc. Generic is the mainstream product in the market, accounting for % sales share globally in 2022.
Amifampridine is widely used in various fields, such as Myasthenia Gravis and Potassium Channel Blocker, etc. Myasthenia Gravis provides greatest supports to the Amifampridine industry development. In 2022, global % sales of Amifampridine went into Myasthenia Gravis filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amifampridine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Jacobus Pharmaceutical
Unichem
BioMarin Pharmaceutical
Wockhardt
Glenmark Pharmaceuticals
Norris Pharm
BLD Pharm
Biosynth AG
Innovapharm
Founder Pharma
BroadPharm
CSNpharm
Merck
Segment by Type
Generic
Patent
Myasthenia Gravis
Potassium Channel Blocker
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Amifampridine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amifampridine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amifampridine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Amifampridine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amifampridine introduction, etc. Amifampridine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Amifampridine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Amifampridine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Amifampridine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Myasthenia Gravis and Potassium Channel Blocker are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Amifampridine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Amifampridine key manufacturers include Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG and Innovapharm, etc. Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical are top 3 players and held % sales share in total in 2022.
Amifampridine can be divided into Generic and Patent, etc. Generic is the mainstream product in the market, accounting for % sales share globally in 2022.
Amifampridine is widely used in various fields, such as Myasthenia Gravis and Potassium Channel Blocker, etc. Myasthenia Gravis provides greatest supports to the Amifampridine industry development. In 2022, global % sales of Amifampridine went into Myasthenia Gravis filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amifampridine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Jacobus Pharmaceutical
Unichem
BioMarin Pharmaceutical
Wockhardt
Glenmark Pharmaceuticals
Norris Pharm
BLD Pharm
Biosynth AG
Innovapharm
Founder Pharma
BroadPharm
CSNpharm
Merck
Segment by Type
Generic
Patent
Segment by Application
Myasthenia Gravis
Potassium Channel Blocker
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Amifampridine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Amifampridine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Amifampridine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Amifampridine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Amifampridine introduction, etc. Amifampridine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Amifampridine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices